The evolving role of CETP inhibition: beyond HDL cholesterol

被引：8

作者：

Ray, Kausik K. ^{[1
]}

Vallejo-Vaz, Antonio J. ^{[2
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Primary Care & Publ Hlth, London W6 8RP, England

[2] St Georges Univ London, Cardiovasc Sci Cardiovasc & Cell Sci Res Inst, London, England

来源：

LANCET | 2015年 / 386卷 / 9992期

关键词：

ACUTE CORONARY SYNDROME; CARDIOVASCULAR EVENTS; LDL CHOLESTEROL; HIGH-RISK; DISEASE; LIPOPROTEIN; ANACETRAPIB; STATINS; LIPIDS; TRIAL;

D O I：

10.1016/S0140-6736(15)60608-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：412 / 414

页数：3

共 14 条

[1] New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention
Anderson, Todd J.
[J]. CANADIAN JOURNAL OF CARDIOLOGY, 2015, 31 (05) : 585 - 587
[2] [Anonymous], 2000, JAMA, DOI DOI 10.1001/jama.2009.1619
[3] HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, Philip
Gotto, Antonio M.
LaRosa, John C.
Maroni, Jaman
Szarek, Michael
Grundy, Scott M.
Kastelein, John J. P.
Bittner, Vera
Fruchart, Jean-Charles
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) : 1301 - 1310
[4] Effects of torcetrapib in patients at high risk for coronary events
Barter, Philip J.
Caulfield, Mark
Eriksson, Mats
Grundy, Scott M.
Kastelein, John J. P.
Komajda, Michel
Lopez-Sendon, Jose
Mosca, Lori
Tardif, Jean-Claude
Waters, David D.
Shear, Charles L.
Revkin, James H.
Buhr, Kevin A.
Fisher, Marian R.
Tall, Alan R.
Brewer, Bryan
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) : 2109 - 2122
[5] Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Cannon, Christopher P.
Shah, Sukrut
Dansky, Hayes M.
Davidson, Michael
Brinton, Eliot A.
Gotto, Antonio M., Jr.
Stepanavage, Michael
Liu, Sherry Xueyu
Gibbons, Patrice
Ashraf, Tanya B.
Zafarino, Jennifer
Mitchel, Yale
Barter, Philip
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (25) : 2406 - 2415
[6] Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, Robert
Peden, John F.
Hopewell, Jemma C.
Kyriakou, Theodosios
Goel, Anuj
Heath, Simon C.
Parish, Sarah
Barlera, Simona
Franzosi, Maria Grazia
Rust, Stephan
Bennett, Derrick
Silveira, Angela
Malarstig, Anders
Green, Fiona R.
Lathrop, Mark
Gigante, Bruna
Leander, Karin
de Faire, Ulf
Seedorf, Udo
Hamsten, Anders
Collins, Rory
Watkins, Hugh
Farrall, Martin
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (26) : 2518 - 2528
[7] Hovingh GK., 2015, Lancet
[8] Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial
Nicholls, Stephen J.
Brewer, H. Bryan
Kastelein, John J. P.
Krueger, Kathryn A.
Wang, Ming-Dauh
Shao, Mingyuan
Hu, Bo
McErlean, Ellen
Nissen, Steven E.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (19): : 2099 - 2109
[9] The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial
Ray, Kausik K.
Ditmarsch, Marc
Kallend, David
Niesor, Eric J.
Suchankova, Gabriela
Upmanyu, Ruchi
Anzures-Cabrera, Judith
Lehnert, Valerie
Pauly-Evers, Meike
Holme, Ingar
Stasek, Josef
van Hessen, Maarten W. J.
Jones, Peter
[J]. EUROPEAN HEART JOURNAL, 2014, 35 (27) : 1792 - 1800
[10] HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
Rohatgi, Anand
Khera, Amit
Berry, Jarett D.
Givens, Edward G.
Ayers, Colby R.
Wedin, Kyle E.
Neeland, Ian J.
Yuhanna, Ivan S.
Rader, Daniel R.
de Lemos, James A.
Shaul, Philip W.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (25) : 2383 - 2393

← 1 2 →